Related references
Note: Only part of the references are listed.Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis
Nadia Terranova et al.
CLINICAL PHARMACOKINETICS (2019)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials
A. M. Novakovic et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis
A. M. Novakovic et al.
AAPS JOURNAL (2017)
Cladribine - an old newcomer for pulsed immune reconstitution in MS
Heinz Wiendl
NATURE REVIEWS NEUROLOGY (2017)
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
Radojka M. Savic et al.
CLINICAL PHARMACOKINETICS (2017)
Sex differences in comorbidity at diagnosis of multiple sclerosis A population-based study
Ruth Ann Marrie et al.
NEUROLOGY (2016)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
Giancarlo Comi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human
Holger Scheible et al.
XENOBIOTICA (2013)
TRANSLOCATION OF NUCLEOSIDE ANALOGS ACROSS THE PLASMA MEMBRANE IN HEMATOLOGIC MALIGNANCIES
Paula X. Fernandez-Calotti et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2011)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation
Haithem Chtioui et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Transepithelial fluxes of adenosine and 2′-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3
Adam N. Elwi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review
Christine E. Garnett et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Cornelia de Wolf et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution
Kazumasa Takenaka et al.
CANCER RESEARCH (2007)
Nucleoside transporters in chronic lymphocytic leukaemia
M Pastor-Anglada et al.
LEUKEMIA (2004)
The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability
LMS Chan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport
AMP Wright et al.
LEUKEMIA (2000)
Share Paper
